Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005561-14
    Sponsor's Protocol Code Number:D9487C00001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-06-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-005561-14
    A.3Full title of the trial
    An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia (DIALIZE-Outcomes)
    Studio Internazionale, Randomizzato, in Doppio Cieco, Controllato con Placebo per Valutare l'Effetto del Ciclosilicato di Sodio Zirconio sugli Eventi Cardiovascolari Correlati all'Aritmia in Pazienti in Trattamento Emodialitico Cronico con Iperkaliemia Ricorrente
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia
    Effetto del Ciclosilicato di Sodio Zirconio sugli Eventi Cardiovascolari Correlati all'Aritmia in Pazienti in Trattamento Emodialitico Cronico con Iperkaliemia Ricorrente
    A.3.2Name or abbreviated title of the trial where available
    DIALIZE-Outcomes
    DIALIZE-Outcomes
    A.4.1Sponsor's protocol code numberD9487C00001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorASTRAZENECA AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca
    B.5.2Functional name of contact pointClinical Study Information Center
    B.5.3 Address:
    B.5.3.1Street Address1800 Concord Pike
    B.5.3.2Town/ cityWilmington DE
    B.5.3.3Post code19803
    B.5.3.4CountryUnited States
    B.5.4Telephone number000000
    B.5.5Fax number000000
    B.5.6E-mailinformation.center@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lokelma
    D.2.1.1.2Name of the Marketing Authorisation holderAstraZeneca AB
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSodium zirconium cyclosilicate 5 g
    D.3.2Product code [AZD7270]
    D.3.4Pharmaceutical form Powder for oral suspension
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 242800-27-7
    D.3.9.2Current sponsor code-
    D.3.10 Strength
    D.3.10.1Concentration unit g gram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lokelma
    D.2.1.1.2Name of the Marketing Authorisation holderAstraZeneca AB
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSodium zirconium cyclosilicate 10 g
    D.3.2Product code [AZD7270]
    D.3.4Pharmaceutical form Powder for oral suspension
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 242800-27-7
    D.3.9.2Current sponsor code-
    D.3.10 Strength
    D.3.10.1Concentration unit g gram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPowder for oral suspension
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPowder for oral suspension
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pre-dialysis hyperkaliemia in patients with end stage renal disease (ESRD) on chronic hemodialysis
    Iperkaliemia pre-dialisi in pazienti con malattia renale allo stadio terminale (ESRD) in emodialisi cronica
    E.1.1.1Medical condition in easily understood language
    Elevated potassium concentration in patients with end stage renal disease on chronic hemodialysis
    Concentrazioni elevate di potassio in pazienti con malattia renale allo stadio terminale in emodialisi cronica
    E.1.1.2Therapeutic area Diseases [C] - Nutritional and Metabolic Diseases [C18]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10020646
    E.1.2Term Hyperkalaemia
    E.1.2System Organ Class 10027433 - Metabolism and nutrition disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of SZC compared with placebo in reducing the incidence of the primary composite endpoint of sudden cardiac death (SCD), all stroke, or hospitalization/intervention/emergency department (ED) visit due to arrhythmias
    Valutare l'efficacia di SZC rispetto al placebo nella riduzione dell'incidenza dell'endpoint primario composto di morte cardiaca improvvisa (SCD), tutti gli infarti o ospedalizzazione/intervento/visite al pronto soccorso dovuti all'aritmia
    E.2.2Secondary objectives of the trial
    - To evaluate the efficacy of SZC compared with placebo in maintaining normokalemia at one year
    - To evaluate the efficacy of SZC compared with placebo in reducing the incidence of hospitalization/intervention/ED visit due to arrhythmias
    - To evaluate the efficacy of SZC compared with placebo in reducing hospitalizations/interventions/ED visits due to arrhythmias
    - To evaluate the efficacy of SZC compared with placebo in reducing the need for rescue therapy for hyperkalemia
    - To evaluate the efficacy of SZC compared with placebo in preventing severe hyperkalemia at one year
    - To evaluate the efficacy of SZC compared with placebo in reducing the incidence of SCD
    - To evaluate the efficacy of SZC compared with placebo in reducing the incidence of all stroke
    - To evaluate the efficacy of SZC compared with placebo in reducing the incidence of cardiovascular (CV) death
    - To evaluate the efficacy of SZC compared with placebo in reducing the incidence of all-cause mortality
    - Valutare l'efficacia di SZC rispetto al placebo nel mantenimento della normokaliemia ad 1 anno
    - Valutare l'efficacia di SZC rispetto al placebo nella riduzione dell'incidenza di ospedalizzazioni/interventi/pronto soccorso dovuti ad aritmia
    - Valutare l'efficacia di SZC rispetto al placebo nel ridurre ospedalizzazioni/interventi/pronto soccorso dovuti ad aritmia
    - Valutare l'efficacia di SZC rispetto al placebo nella riduzione della necessità di utilizzare terapie di salvataggio per l'iperkaliemia
    - Valutare l'efficacia di SZC rispetto al placebo nel prevenire l'iperkaliemia severa ad un anno
    - Valutare l'efficacia di SZC rispetto al placebo nel ridurre l'incidenza di SCD
    - Valutare l'efficacia di SZC rispetto al placebo nel ridurre l'incidenza di infarto
    - Valutare l'efficacia di SZC rispetto al placebo nel ridurre l'incidenza di eventi cardiovascolari (CV)
    - Valutare l'efficacia di SZC rispetto al placebo nel ridurre l'incidenza di mortalità dovuta a qualsiasi causa
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the
    protocol
    2. Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses
    3. Must be = 18 years of age, at the time of signing the ICF.
    4. Receiving hemodialysis (or hemodiafiltration) 3 times a week for treatment of ESRD for = 4 months before enrollment
    5. Must have hemodialysis access consisting of an arteriovenous fistula, arteriovenous graft, or tunneled (permanent) catheter which is expected
    to remain in place for the entire duration of the study
    6. At least 2 out of 3 pre-dialysis S K = 5.5 mmol/L after the LIDI during screening
    7. Negative pregnancy test for female participants of childbearing potential
    8. Female participants must be 1 year postmenopausal, surgically sterile, or using one highly effective form of birth control (defined as one that
    can achieve a failure rate of less than 1% per year when used consistently and correctly). They should have been stable on their
    chosen method of birth control for a minimum of 3 months before entering the study and willing to remain on the birth control until 12
    weeks after the last dose.
    1. In grado di fornire il consenso informato scritto che include la compliance con le richieste e le restrizioni descritte nell'ICF e nel protocollo
    2. Fornire il consenso informato scritto, firmato e datato prima di ogni procedura obbligatoria specifica dello studio, tra cui i prelievi e le analisi
    3. Età pari o maggiore di 18 anni nel momento in cui viene firmato l'ICF.
    4. Sottoposti ad emodialisi (o emodiafiltrazione) 3 volte a settimana per il trattamento della ESRD da 4 mesi o più prima dell'arruolamento
    5. Devono avere accesso all'emodialisi che consiste in fistola artero-venosa, innesto artero-venoso o catetere tunnellizzato (permanente) mantenuto durante l'intera durata dello studio
    6. Almeno 2 dei 3 risultati di S-K = 5.5 mmol/L dopo il LIDI durante lo screening
    7. Test di gravidanza negativo per le donne partecipanti in età fertile
    8. Le donne partecipanti devono essere in post-menopausa da 1 anno, oppure chirurgicamente sterili oppure devono usare uno tra i sistemi anticoncezionali ad alta efficacia (ovvero che possono raggiungere un tasso di errore inferiore all'1% all'anno quando usato correttamente). Le partecipanti devono essersi dimostrate costanti nell'uso del metodo anticoncezionale scelto per almeno 3 mesi prima di entrare nello studio e dimostrare la volontà di mantenerlo fino a 12 settimane dopo l'ultima dose.
    E.4Principal exclusion criteria
    1. Pseudohyperkalemia secondary to hemolyzed blood specimen (this situation is not considered screening failure, sampling or full screening
    can be postponed to a later time as applicable)
    2. Presence of cardiac arrhythmias or conduction defects that require immediate treatment
    3. Participants who have a pacemaker or implantable cardiac defibrillator
    4. Any medical condition, including active, clinically significant infection or liver disease, that in the opinion of the investigator or sponsor may
    pose a safety risk to a participant in this study, confound safety or efficacy assessment and jeopardize the quality of the data, or interfere
    with study participation, or any other restrictions or contraindications in the local prescribing information for SZC
    5. History of QT prolongation associated with other medications that required discontinuation of that medication
    6. Congenital long QT syndrome
    7. QTcF > 550 msec
    8. Symptomatic or uncontrolled AF despite treatment, or asymptomatic sustained ventricular tachycardia
    9. Treated with SPS (eg, Kayexalate, Resonium), CPS (Resonium Calcium), patiromer (Veltassa), or SZC (Lokelma) within 7 days before screening
    10. Participation in another clinical study with an investigational product administered within one month before screening
    11. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
    12. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study
    procedures, restrictions, and requirements
    13. Previous randomization in the present study
    14. Females who are pregnant (confirmed with positive pregnancy test or a uterine ultrasound if pregnancy test result is questionable),
    breastfeeding, or planning to become pregnant during the study
    15. Known hypersensitivity or previous anaphylaxis to SZC or to components thereof
    16. Scheduled date for living donor kidney transplant
    1. Pseudoiperkaliemia secondaria al campione di sangue emolizzato (questa situazione non è considerata screening failure, il prelievo o lo screening completo possono essere posticipati, se applicabile)
    2. Presenza di aritmia cardiaca o di alterazioni della conduzione che richiedono trattamento immediato
    3. Partecipanti che hanno un pacemaker o un defibrillatore cardiaco impiantabile
    4. Qualsiasi condizione medica, incluse infezioni attive, clinicamente significative o malattie epatiche, che secondo l'opinione dello sperimentatore o dello sponsor potrebbero mettere a rischio la sicurezza del paziente nello studio, confondere le valutazioni di sicurezza ed efficacia e mettere a rischio la qualità dei dati, o interferire con la partecipazione allo studio o con qualsiasi altra restrizione o controindicazione della prescrizione locale per SZC
    5. Storia di prolungamento del QT associato con altri trattamenti, che ha portato all'interruzione dell'assunzione di questi ultimi
    6. Sindrome del QT lungo congenita
    7. QTcF > 550 msec
    8. AF sintomatica o non controllata nonostante il trattamento, oppure tachicardia ventricolare sostenuta asintomatica
    9. Trattati con SPS (per es., Kayexalate, Resonium), CPS (Resonium Calcium), patiromer (Veltassa) o SZC (Lokelma) nei 7 giorni precedenti lo screening
    10. Partecipazione in un altro studio clinico con la somministrazione del prodotto sperimentale nel mese precedente lo screening
    11. Coinvolto nella pianificazione e/o conduzione dello studio (si applica sia allo staff di AstraZeneca, sia allo staff del centro)
    12. Secondo il giudizio dello sperimentatore, il soggetto non dovrebbe partecipare allo studio in quanto è improbabile che riesca a sottostare alle procedure, restrizioni e ai requisiti dello stesso
    13. Randomizzato precedentemente nel presente studio
    14. Donne in gravidanza (confermata da un test di gravidanza positivo, o da ultrasuoni uterini nel caso il risultato del test non sia chiaro), in allattamento o che programmano una gravidanza durante lo studio
    15. Nota ipersensibilità o precedente anafilassi ad SZC e ai suoi componenti
    16. Hanno già una data pianificata per il trapianto di rene
    E.5 End points
    E.5.1Primary end point(s)
    Time to first occurence of SCD, stroke, or hospitalization/intervention/ED visit due to arrhythmias (AF, bradycardia, asystole, VT)
    Tempo fino alla prima occorrenza di SCD, infarto o ospedalizzazione/intervento/visita al pronto soccorso dovuti ad aritmie (AF, bradicardia, asistole, VT)
    E.5.1.1Timepoint(s) of evaluation of this end point
    It is expected that the primary endpoint events will be collected for an average of 25 months post-randomization. The individual follow-up times will vary, as the study is event-driven aiming for 770 events.
    E' atteso che gli eventi dell'endpoint primario verranno raccolti in una media di 25 mesi dopo la randomizzazione. I tempi individuali di follow-up saranno variabili, in quanto lo studio è event-driven e mira all'obiettivo di 770 eventi.
    E.5.2Secondary end point(s)
    - S-K of 4.0-5.5 mmol/L (yes/no) after the LIDI at the 12 month visit
    - Time to first occurrence of hospitalization/intervention/ED visit due to arrhythmias (AF, bradycardia, asystole, VT)
    - Number of hospitalizations/interventions/ED visits due to arrhythmias (AF, bradycardia, asystole, or VT)
    - Time to first instance of rescue therapy use for hyperkalemia
    - S-K > 6.5 mmol/L (yes/no) after the LIDI at the 12 month visit
    - Time to SCD
    - Time to first occurrence of stroke
    - Time to CV death
    - Time to death of any cause
    - S-K di 4.0-5.5 mmol/L (si/no) dopo il LIDI alla visita dei 12 mesi
    - Tempo fino alla prima occorrenza di ospedalizzazione/intervento/visita al pronto soccorso a causa di aritmie (AF, bradicardia, asistole, VT)
    - Numero di ospedalizzazioni/interventi/visite al pronto soccorso a causa di aritmie (AF, bradicardia, asistole, VT)
    - Tempo fino alla prima occcasione d'uso di terapia di salvataggio per iperkaliemia
    - S-K > 6.5 mmol/L (si/no) dopo il LIDI alla visita dei 12 mesi
    - Tempo fino alla SCD
    - Tempo fino alla prima occorrenza di infarto
    - Tempo fino alla morte cardiovascolare
    - Tempo fino alla morte dovuta a qualsiasi causa
    E.5.2.1Timepoint(s) of evaluation of this end point
    It is expected that the secondary endpoint events will be collected for an average of 25 months post-randomization. The individual follow-up
    times will vary, as the study is event-driven aiming for 770 events.
    S-K related endpoints will be evaluated at 12 months after randomization.
    E' atteso che gli eventi dell'endpoint secondario vengano raccolti in media nei 25 mesi dopo la randomizzazione. Il follow-up individuale potrebbe variare, in quanto lo studio è event-driven con l'obiettivo di 770 eventi.
    Gli endpoint correlati ad S-K verranno valutati ai 12 mesi dopo la randomizzazione.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Canada
    China
    Japan
    Mexico
    Peru
    Russian Federation
    Taiwan
    Ukraine
    United States
    Vietnam
    Austria
    Bulgaria
    Germany
    Hungary
    Slovakia
    Spain
    United Kingdom
    Czechia
    Argentina
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study is defined as the last expected visit/contact of the last patient undergoing the study.
    La fine dello studio è definita come gli ultimi attesi visita/contatto dell'ultimo paziente dello studio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1550
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 750
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state69
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 650
    F.4.2.2In the whole clinical trial 2300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None.
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-31
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-04-29
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2023-11-30
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 22:05:09 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA